Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Amikacin to Prevent Ventilator Associated Pneumonia
NCT03149640Phase 3Completed
- Sponsor
- University Hospital Tours
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Inhaled amikacin with Placebo (2 arms). Primary endpoint: Incidence of a first VAP episode at 28 days. Started Jul 2017; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03149640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149640.